Early Breast Cancer

Oncology·MeSH: Breast Neoplasms

Prevalence

287.0 / 100K

Incidence

128.0 / 100K/yr

18 drugs in development·7 companies·7 clinical trials

Drug Pipeline by Phase

Approved(2)

Drug	Company
kisqali femara co-pack	Novartis AG (NVS)
Verzenio®	ELI LILLY & Co (LLY)

Phase 3(13)

Drug	Company
ansastrozole	Novartis AG (NVS)
Camizestrant	ASTRAZENECA PLC (AZN)
GnRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
goserelin	Novartis AG (NVS)
Goserelin	Novartis AG (NVS)
Hormone Therapy	Filana Therapeutics Inc. (FLNA)
leuprolide	Novartis AG (NVS)
Leuprolide	Novartis AG (NVS)
LHRH Agonist	ENANTA PHARMACEUTICALS INC (ENTA)
Pertuzumab IV	Filana Therapeutics Inc. (FLNA)
Pertuzumab IV	Merus N.V. (MRUS)
Physician's Choice of Endocrine Therapy	ENANTA PHARMACEUTICALS INC (ENTA)
taxane	GH Research PLC (GHRS)

Phase 2(1)

Drug	Company
lhrh analogue	GH Research PLC (GHRS)

Phase 4(2)

Drug	Company
Ansastrozole	Novartis AG (NVS)
Investigator's Choice of Chemotherapy	Filana Therapeutics Inc. (FLNA)

BioSniper tracks 18 drugs in development for Early Breast Cancer across 7 companies.

There are 7 clinical trials targeting Early Breast Cancer tracked by BioSniper.

The estimated prevalence of Early Breast Cancer is approximately 287.0 per 100,000 population.

Full trial data, competitive analysis, and AI-powered pipeline tracking.